Phase 1 Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion With Clopidogrel in Healthy Subjects

Drug Interaction Clinical Trial

Official title:

A Phase 1, Open-label, 2-period, Fixed-sequence Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion Coadministered With Clopidogrel in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02560688
• Other study ID #: DS1040-A-E106
• Secondary ID: 2015-003018-26
• Status: Completed
• Phase: Phase 1
• Start date: December 2015
• Est. completion date: March 2016

Study information

• Verified date: June 2016
• Source: Daiichi Sankyo, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is being conducted to test the hypothesis that coadministration of clopidogrel with DS-1040b will be safe and well tolerated. Subjects entering the study will initially receive a single 12 hour infusion of DS-1040b, to generate data on the effect of DS-1040b alone. After a wash-out period (to ensure that no DS-1040b is left in the blood) subjects will receive repeated clopidogrel doses over 5 days to generate data on the effect of clopidogrel alone. On the sixth day subjects will receive both DS-1040b and clopidogrel, and the effects will be compared to when the two treatments were given alone.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: March 2016
• Est. primary completion date: March 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Healthy male or female subjects of non-childbearing potential; subjects must be aged 18 years to 60 years, inclusive.

• Subjects with a body mass index (BMI) of 18 kg/m2 to 30 kg/m2, inclusive, and weighing between 50 kg and 100 kg, inclusive. BMI is calculated as weight [kg]/(height [m])*2.

• Subjects must be in good health as determined by medical history, physical examination and Screening investigations, and taking no regular medication.

• Female subjects must be of non-childbearing potential as follows:

• Must be postmenopausal (the last menstrual period was at least 12 months before Screening, and a follicle-stimulating hormone [FSH] test at Screening confirms postmenopausal status); or

• Must be surgically sterile having undergone hysterectomy, bilateral oophorectomy, bilateral salpingectomy and/or bilateral tubal ligation.

• Willing to comply with all study restrictions, including the use of contraception, concomitant medication and dietary and lifestyle restrictions.

• Possessing sufficient intelligence to understand the nature of the study and any hazards of participating in it, and the ability to communicate satisfactorily with the Investigator and to participate in, and comply with the requirements of, the entire study.

• Has given written consent to participate after reading the informed consent form (ICF), and after having the opportunity to discuss the study with the Investigator or his/her delegate.

• Have given written consent to have his/her data entered into The Overvolunteering Prevention System.

Exclusion Criteria:

• Clinically relevant abnormal history, physical findings, ECG findings or laboratory values that could interfere with the objectives of the study or the safety of the subject.

• Presence or history of acute or chronic illness, including (but not limited to) liver or kidney disease, hypertension, seizures, or any known impairment of endocrine, or other specific body-organ dysfunction.

• Presence or history of severe adverse reaction to any medicine.

• Presence or history of malignant disease.

• Surgery (eg, stomach bypass) or medical condition that might affect absorption of medicines.

• Significant illness within 4 weeks before the dose of study medication.

• Participation in another clinical trial of a new chemical entity or a prescription medicine within the previous 3 months, or unwilling to abstain from participating in other clinical trials during the study and for 3 months after receipt of study medication.

• Participation in another clinical study with DS-1040b.

• Day-1 bleeding time greater than 10 minutes.

• Blood pressure (BP) and heart rate (HR) in semi-supine position at the Screening examination outside the ranges 90 to 140 mmHg systolic, 40 to 90 mmHg diastolic; HR 40 to 100 beats/min. A subject with vital signs outside the reference range for the population being studied may be included at the Investigator's discretion if it is unlikely to introduce additional risk factors and will not interfere with study procedures.

• Abnormal electrocardiogram ECG waveform morphology at Screening that would preclude accurate measurement of the uncorrected QT interval (QT) duration.

• QT interval for HR corrected using Fridericia's formula (QTcF) interval duration > 430 msec for men or > 450 msec for women, obtained as an average from the measurements on triplicate Screening ECGs.

• Use of any prescription medicine, over-the-counter (OTC) medications, herbal remedies (such as St John's Wort), or food known to be strong inhibitors or strong inducers of CYP enzymes during the 30 days before the dose of study medication; use of any other prescription or OTC medicine (except as permitted, including dietary supplements or herbal remedies, during the 7 days before the first dose of study medication.

• Consumption of certain foods or beverages before the dose and throughout the study period.

• Loss of more than 400 mL blood plasma, platelets or any other blood components during the 3 months before the first dose of study medication, or unwilling to abstain from doing so during the study and for 3 months after receipt of study medication.

• Abuse of drugs or alcohol in the past, or intake of more than 21 units of alcohol weekly (for males) or 14 units of alcohol weekly (for females).

• Use of tobacco products or nicotine-containing products during the 3 months before the dose of study medication.

• Male subjects not using adequate contraceptive methods. Male subjects have to agree to use contraception (condom with spermicide) in addition to having their female partner (if of childbearing potential) use another form of contraception (eg, an intrauterine device, diaphragm with spermicide, oral contraceptive, injectables, or subdermal hormonal implant) from the first dose until 4 months following the last dose administration. Also, the male subjects must not donate sperm until at least 4 months following the last dose administration.

• Evidence of acute or chronic infectious disease at Screening, including: positive Hepatitis B Surface Antigen (HBsAg), Hepatitis C Virus (HCV) antibody, or Human Immunodeficiency Virus (HIV) antibody.

• CYP2C19 poor metabolizers.

• Subjects who have used anticoagulants (ie, warfarin, low molecular weight heparin, thrombin inhibitors), antiplatelet (eg, clopidogrel), nonsteroidal anti-inflammatory drug, and/or aspirin within 30 days prior to Period 1, Day 1.

• Subjects with a history of major bleeding or major surgical procedure of any type within 6 months before Period 1, Day 1.

• Subjects with a history of peptic ulcer, gastrointestinal bleeding including haematemesis, melena, or bleeding from haemorrhoids.

• Subjects with a history of minor bleeding episodes such as epistaxis, rectal bleeding (spots of blood on toilet paper), or gingival bleeding within 3 months before Period 1, Day 1.

• Subjects who have any family history, suspected or documented, of coagulopathy or haemoglobinopathy or evidence of abnormal coagulation parameters (eg, PT, INR or aPTT) at Screening.

• Subjects with an estimated glomerular filtration rate (eGFR) at Screening using the Modification of Diet in Renal Disease (MDRD) equation < 90 mL/min.

• Likely possibility that the subject will not cooperate with the requirements of the protocol.

• Objection by General Practitioner to subjects entering the study

Related Conditions & MeSH terms

• Drug Interaction

Intervention

Drug:
• DS-1040b
20 mg single 12-hour intravenous infusion
• Clopidogrel
Clopidogrel (Plavix) administered orally 300 mg loading dose on Day 1 followed by 75 mg daily on Days 2-5

Locations

Country	Name	City	State
United Kingdom	Hammersmith Medicines Research	London

Sponsors (1)

Lead Sponsor	Collaborator
Daiichi Sankyo, Inc.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of adverse events	Evaluation of the safety and tolerability of DS-1040 administered alone or with clopidogrel, as determined by adverse events,from the time of dosing up to 5 days postdose.	5 days
Primary	physical exam profile	Evaluation of the safety and tolerability of DS-1040 administered alone or with clopidogrel, as determined by physical examination findings, vital signs, 12-lead electrocardiograms (ECGs), clinical safety laboratory tests from the time of dosing up to 5 days postdose.	5 days
Primary	bleeding time measurements	Evaluation of the safety and tolerability of DS-1040 administered alone or with clopidogrel, as determined by bleeding time assessments from the time of dosing up to 5 days postdose.	5 days
Secondary	DS-1040b plasma concentration profile Time of Maximum plasma concentration(Tmax)	Plasma concentrations of DS-1040 and derived PK parameters up to 5 days after a single 20 mg intravenous infusion of DS-1040 (alone and with clopidogrel).	5 days
Secondary	DS-1040b plasma concentration profile Area Under the plasma concentration time Curve (AUC)	Plasma concentrations of DS-1040 and derived PK parameters up to 5 days after a single 20 mg intravenous infusion of DS-1040 (alone and with clopidogrel).	5 days
Secondary	DS-1040b plasma concentration profile Maximum plasma concentration (Cmax)	Plasma concentrations of DS-1040 and derived PK parameters up to 5 days after a single 20 mg intravenous infusion of DS-1040 (alone and with clopidogrel).	5 days
Secondary	changes in pharmacodynamic profile single administration	Change in baseline of pharmacodynamic parameters (thrombin activatable fibrinolysis inhibitor activity, clot lysis, plasma D-dimer, ADP-induced platelet aggregation) up to 5 days after a single 20 mg intravenous infusion of DS-1040 (alone and with clopidogrel).	5 days
Secondary	clopidogrel plasma concentration profile Tmax	Plasma concentrations of Clopidogrel Active Metabolite and derived PK parameters after repeated Clopidogrel administration (alone and with DS-1040)	5 days
Secondary	clopidogrel plasma concentration profile AUC	Plasma concentrations of Clopidogrel Active Metabolite and derived PK parameters after repeated Clopidogrel administration (alone and with DS-1040)	5 days
Secondary	clopidogrel plasma concentration profile Cmax	Plasma concentrations of Clopidogrel Active Metabolite and derived PK parameters after repeated Clopidogrel administration (alone and with DS-1040)	5 days
Secondary	changes in pharmacodynamic profile repeated administration	Change in baseline of pharmacodynamic parameters (thrombin activatable fibrinolysis inhibitor activity, clot lysis, plasma D-dimer, ADP-induced platelet aggregation) up to 5 days after repeated Clopidogrel administration (alone or with DS-1040)	5 days